71
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Docetaxel and Its Nanoformulations: How Delivery Strategies Could Impact the Therapeutic outcome?

, , & ORCID Icon
Pages 755-759 | Received 26 Jul 2020, Accepted 12 Aug 2020, Published online: 01 Sep 2020
 

Financial & competing interests disclosure

SERB-Department of Science and Technology (DST) (YSS/2014/000521) and DST-Rajasthan (S.No. P7(3)/VPro./RandD/2016/3228) is duly acknowledged for the financial support to D Chitkara. Council for Scientific and Industrial Research (CSIR) (File no 09/719(0087)/2018-EMR-1) is duly acknowledged for senior research fellowship (SRF) to S Sharma. The authors (D Chitkara and A Mittal) are the founding directors of Nanobrid Innovations Private Limited, India, that is involved in the development of nanotechnology-based products. They have a business and/or financial interest in the operations of the company. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.